* Says drug well-tolerated in asthma patients
* Says incidence of adverse events comparable to placebo
* Says no significant abnormalities in vital signs
May 19 Theravance Inc (THRX.O) said data
presented by partner GlaxoSmithKline (GSK.L) from a mid-stage
trial showed that their experimental asthma treatment was
well-tolerated in patients, with no significant adverse
Vilanterol trifenatate, coded GW642444M, when taken in
combination with an inhaled steroid, facilitated rapid and
prolonged airflow in patients with mild to moderate persistent
asthma over 24 hours after taking the drug, Theravance said in
a regulatory filing.
Theravance said incidence and severity of adverse events in
patients treated with the drug were comparable to those treated
with a dummy drug.
Single doses of the drug did not show any clinically
significant abnormalities in vital signs in asthma patients,
suggesting potential for a daily dosage, the company said.
Shares of Theravance closed at $14.23 Wednesday on Nasdaq.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by